Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Colorectal cancer marker composition and application thereof

A marker, colorectal tumor technology, applied in the field of biomedicine, can solve the problem of no significant improvement, achieve high accuracy, reduce medical burden, and improve survival rate

Pending Publication Date: 2019-10-25
THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Kuo et al. reported that the marker phospholipid scramblase 1 (PLSCR1) combined with CEA to diagnose colorectal cancer, after the combination, the sensitivity increased from 80% to 85%, without significant improvement (Y.Kuo et al., Identification of phospholipid scramblase1 as a biomarker and determination of its prognostic value for colorectal cancer. Molecular medicine; 17,41-47(2011)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Colorectal cancer marker composition and application thereof
  • Colorectal cancer marker composition and application thereof
  • Colorectal cancer marker composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Embodiment 1 sample source and analysis

[0092] From September 2018 to December 2018, 120 patients (stages I, II, III, and IV) diagnosed with colorectal cancer in the Sixth Affiliated Hospital of Sun Yat-sen University were collected, all of whom were confirmed by imaging and pathological examination. All pathological results were obtained by tissue biopsy. The patient had no serious organ disease, and had not received chemotherapy, radiotherapy or surgery. A total of 90 cases were collected as controls from a healthy population at the same time. The inclusion criteria for healthy controls were that there were no obvious abnormalities in the results of blood routine and biochemical tests, and no infectious diseases such as hepatitis B. The basic information is shown in Table 2. All blood samples were collected using EDTA anticoagulant tubes. Plasma separation was completed within 6 hours at room temperature, centrifuged at 3000 rpm for 2 minutes, and the plasma was t...

Embodiment 2

[0097] Embodiment 2 Tumor marker content determination method

[0098] In the present invention, the content of PON1 adopts enzyme-linked immunosorbent assay (ELISA) detection, selects commercial kit RayBiotech Human PON1ELISA Kit, Biotek Elx800 microplate reader 450nm, Biotek Elx50 washer, pipette, small centrifuge tube, deionized Water, Sigmaplot analysis software, etc. The contents of CEA, CA125 and CA199 were detected by chemiluminescent enzyme immunoassay (CLEIA) in Abbott I2000.

[0099] (1) Equilibrate the kit and samples to room temperature (18-25°C);

[0100] (2) The diluent is diluted 5 times with deionized water for later use;

[0101] (3) Plasma samples were diluted 40 times for later use;

[0102] (4) Standard product preparation: Centrifuge the small tube of the standard product, then add 400 μL of 1× diluent to the small tube of the standard product, and mix well to obtain a 50 ng / mL standard product stock solution; draw 40 μL of the standard product stock so...

Embodiment 3

[0115] Example 3 Tumor markers to the diagnostic efficacy test results of colorectal cancer

[0116] 1. Using CEA, CA125, CA199 and PON1 as tumor markers, the corresponding Youden index and cutoff values ​​obtained from the samples in Example 1 detected by the measurement method in Example 2 are shown in Table 3.

[0117] Table 3 The maximum value and cutoff value of Youden index corresponding to CEA, CA125, CA199, PON1

[0118]

[0119] 2. Combined indicators to predict the diagnostic efficacy of CRC

[0120] CEA, CA125, CA199, PON1 various combined schemes to detect colorectal cancer diagnostic efficiency comparison of the sample in Example 1. Wherein, the data are calculated for 120 colorectal cancer patients and 90 healthy controls in Example 1.

[0121] The ROC curve is obtained by Logistic regression, in which the independent variable is the corresponding index, and the dependent variable is the cancer status. The probability of each individual suffering from cancer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of medicine and relates to a marker composition, application thereof in the preparation of a colorectal cancer diagnosis reagent and a colorectal cancer diagnosis reagent / kit. The marker composition has the advantages that markers PON1 and CEA in serum are combined to obtain the marker composition, the marker composition has extremely high correlation with colorectal cancer, the sensitivity of the marker composition can reach 92.5-95%, and the specificity of the marker composition even can reach up to 100%; the marker composition has high sensitivity and specificity in the diagnosis of early-stage colorectal cancer, the sensitivity can reach 92.3-94.9%, the specificity can also reach 100%, the sensitivity and the specificity are quite rare in clinical practice, the marker composition can be used for the early detection of the colorectal cancer, time can be bought for patients, the patients can be treated as soon as possible, and the survival rate of the patients can be increased.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a colorectal cancer marker combination and application thereof and a diagnostic reagent / kit for colorectal tumors. Background technique [0002] Global cancer statistics predict 18.1 million new cancer cases and 9.6 million deaths in 2018. Colorectal cancer (CRC) is a common malignant tumor of the digestive tract. The incidence and mortality of colorectal cancer in my country rank third among all malignant tumors, and the incidence is still rising. Studies have shown that screening individuals with colorectal cancer risk factors can lead to early diagnosis of cancer, reduce mortality, and even reduce the incidence of colorectal cancer by finding and removing adenomas. The United States began to promote early screening of colorectal cancer as early as the 1980s, and the 5-year survival rate of colorectal cancer patients in the United States has reached 90%, which shows that the developme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886G01N33/57419G01N33/57484C12Q2600/158
Inventor 杨湘玲张瀞丹韦丽丽赵璐肖艳红胡素华钟硕贤徐重刘焕亮
Owner THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com